H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (NASDAQ:BTAI) Inc on Monday, setting a price target of $175, which is approximately 222.40% above the present share price of $54.28.
Selvaraju expects Bioxcel Therapeutics Inc to post earnings per share (EPS) of -$1.07 for the fourth quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Bioxcel Therapeutics, with an average price target of $105.67.
The analysts price targets range from a high of $175 to a low of $60.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$24.77 million. The company's market cap is $1.32 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.4% and a 56.74% success rate.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.